SAB Biotherapeutics SAB-142 receives Breakthrough T1D grant
Breakthrough T1D awarded a grant to support the PRISE-hATG study evaluating SAB-142 for new-onset type 1 diabetes patients.
View filing at SEC.gov →1 most recent filing and news item mentioning SABS. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/SABS/news?limit=20"
Pull SABS filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayBreakthrough T1D awarded a grant to support the PRISE-hATG study evaluating SAB-142 for new-onset type 1 diabetes patients.
View filing at SEC.gov →